Obituaries

Hunein Maassab, 87; created nasal flu vaccine spray

NEW YORK — Hunein Maassab witnessed a transformational moment in public health when he was a young doctoral student at the University of Michigan. It happened on April 12, 1955, the day his mentor, Dr. Thomas Francis Jr., announced that he had completed a vast field trial involving nearly 2 million children to determine the effectiveness of what at the time seemed like a miracle drug: a vaccine for polio.

The vaccine had been developed by one of Francis’ former lab researchers, Jonas Salk, and Dr. Maassab had worked on the field trial, studying blood samples. Listening as Francis, a renowned virologist who had developed some of the first flu vaccines, described the study in a campus auditorium, Dr. Maassab knew the direction he wanted his life to take.

Advertisement

“That was his initial inspiration, that he wanted to develop something like that for humankind,” Rashid L. Bashshur, a close friend, said. “That would make his life worthwhile.”

Nearly half a century later, in June 2003 — after decades of starts and stops, of tinkering and test trials, of government reviews, patent applications, and corporate twists — Dr. Maassab’s work came to fruition when the Food and Drug Administration declared a nasal-spray flu vaccine he had developed safe for healthy people ages 5 to 49 who are not pregnant. It carried the brand name FluMist.

Get Today's Headlines in your inbox:
The day's top stories delivered every morning.
Thank you for signing up! Sign up for more newsletters here

Not long afterward, the vaccine was approved for children as young as 2. It is now commonly administered, with many people choosing it over an injection.

Dr. Maassab, who was born in Syria and began using John as a first name after he moved to the United States in the late 1940s, was 87 when he died on Feb. 1 in North Carolina.

Unlike previous flu vaccines, Dr. Maassab’s spray used a live version of the influenza virus that had been attenuated, or weakened, so as not to cause the flu. He also adapted the vaccine so that it activates quickly upon entering the body in the relatively cool region of the nasal passages. Getting it right, and getting it approved, took a long, long time.

Advertisement

As early as 1960 he had isolated a strain of flu virus for developing a vaccine. By 1967, he had written about his work in the journal Nature. Over the next three decades, working with several colleagues, particularly Brian R. Murphy at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, he completed the hard work of science — developing dozens of live attenuated viruses, documenting the genetic makeup of certain flu viruses, developing ways of quickly adjusting vaccines to the variants of the flu that emerge each year.

More than 70 studies and trials were conducted, covering more than 9,000 volunteers. By the late 1990s, tests showed that the vaccine successfully prevented the flu 85 percent of the time, a better rate than that for the injected, nonliving vaccine. (Tests since then have shown the nasal spray to be even more effective.)

“I feel in a sense that I have accomplished my life’s dream,” Dr. Maassab, who had retired, said after FluMist was finally approved. “I spent all my lifetime developing this vaccine.”

Dr. Maassab was born in Damascus. He enrolled at the University of Missouri, where he received a bachelor’s degree in biology in 1950 and a master’s in physiology and pharmacology in 1952. He then moved to Michigan, where he earned a master’s degree in public health in 1954 and his doctorate in epidemiology in 1956.

You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.